Core Viewpoint - A securities fraud class action lawsuit has been filed against Soleno Therapeutics, Inc. for allegedly making materially false and misleading statements regarding its Phase 3 clinical trial program for its product DCCR, which is intended for treating hyperphagia in individuals with Prader-Willi syndrome [1][4][5]. Company Overview - Soleno Therapeutics, Inc. is a pharmaceutical company based in Redwood City, California, focused on developing therapies for rare diseases. Its only commercial product is diazoxide choline extended-release tablets (DCCR) [3]. Lawsuit Details - The lawsuit was filed on behalf of investors who purchased Soleno common stock between March 26, 2025, and November 4, 2025, and alleges that the company failed to disclose significant safety concerns related to DCCR, which could affect its commercial viability [1][5]. - Key allegations include misrepresentation of safety concerns in the Phase 3 clinical trial, leading to greater risks than disclosed, and potential adverse events post-launch, which could impact patient adoption and regulatory standing [4][7]. Financial Impact - Following the release of financial results on November 4, 2025, Soleno's stock price dropped over 26% due to concerns raised by a report from Scorpion Capital regarding the clinical trial program and its implications for DCCR's market performance [7]. Investor Actions - Investors affected by the alleged fraud are encouraged to contact Kessler Topaz Meltzer & Check, LLP for potential recovery options, with a deadline to seek lead plaintiff status set for May 5, 2026 [2][5][9].

Group 1 - A class action lawsuit has been filed against Beyond Meat, Inc. on behalf of investors who acquired its securities between February 27, 2025, and November 11, 2025 [1] - Beyond Meat is headquartered in El Segundo, California, and specializes in developing plant-based food products sold under the "Beyond" brand [2] - The company has committed to achieving EBITDA-positive operations by the end of 2026, focusing on expense reduction, margin improvement, and operational efficiency [3] Group 2 - On October 24, 2025, Beyond Meat announced an expected material impairment charge, leading to a stock price drop of over 23% in one trading day [4] - Subsequent disclosures in November 2025 regarding delayed SEC filings and $77.4 million in impairment charges resulted in further stock declines of approximately 16%, 9%, and 9%, causing significant investor losses [4]

NASDAQ: DRVN: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Driven Brands Holdings Inc. Accessibility StatementSkip NavigationDid you buy DRVN common stock between May 9, 2023, and February 24, 2026?Affected Driven Brands Holdings Inc. Investor SummaryWho: Driven Brands Holdings Inc. (NASDAQ: DRVN)What: Securities fraud class action lawsuit filedClass Period: May 9, 2023, through February 24, 2026Deadline to Seek Lead Plaintiff Status: May 8, 2026 ...

Core Viewpoint - A securities fraud class action lawsuit has been filed against uniQure N.V. for misleading investors regarding its gene therapy drug AMT-130 during the specified Class Period [2][4][5]. Group 1: Lawsuit Details - The lawsuit was filed by Kessler Topaz Meltzer & Check, LLP on behalf of investors who purchased uniQure ordinary shares between September 24, 2025, and October 31, 2025 [2][7]. - The deadline for investors to seek lead plaintiff status is April 13, 2026 [3][9]. - The case is titled Scocco v. uniQure N.V., et al., and is being heard in the United States District Court for the Southern District of New York [2]. Group 2: Allegations Against uniQure - The complaint alleges that uniQure made materially false and misleading statements regarding its Phase I/II clinical trials and the timeline for its Biologics License Application (BLA) submission to the FDA [4][5]. - Specific allegations include that the design of the Pivotal Study was not fully approved by the FDA and that uniQure downplayed the likelihood of needing to delay its BLA timeline due to additional studies [5][6]. - On November 3, 2025, uniQure disclosed that the FDA no longer agreed that the data from the Phase I/II studies would be adequate for BLA submission, leading to a significant drop in share price [6][8]. Group 3: Impact on Share Price - Following the disclosure on November 3, 2025, uniQure's share price fell by $33.40, or over 49%, from $67.69 to $34.29 per share [8].

Core Viewpoint - A class action lawsuit has been filed against BellRing Brands, Inc. on behalf of investors who acquired its securities during the specified class period, highlighting potential issues with the company's performance and market position [1][2]. Company Overview - BellRing Brands, Inc. is headquartered in St. Louis, MO, and markets nutrition products including ready-to-drink protein shakes, nutrition drinks, powders, and protein bars under the Premier Protein and Dymatize brands [2]. Financial Performance and Stock Impact - On May 6, 2025, BellRing's CFO indicated that several key retailers reduced their inventory levels, which was expected to negatively impact third-quarter growth by a mid-single-digit percentage. Following this announcement, BellRing's stock price fell by $14.88, or 19%, from $78.43 to $63.55 per share [3]. - On August 4, 2025, BellRing narrowed its fiscal year 2025 net sales outlook due to competitive pressures, resulting in a significant stock price drop of $17.46, or 33%, from $53.64 to $36.18 per share the following day [4].

Core Viewpoint - Hub Group Inc. is under investigation for potential violations of federal securities laws, specifically regarding misrepresentation of transportation costs and accounts payable for the first nine months of 2025 [1][2]. Group 1: Investigation Details - Bleichmar Fonti & Auld LLP is leading the investigation into Hub Group for possible misrepresentation of its financial data [1]. - The investigation focuses on whether Hub Group inaccurately reported its purchased transportation costs and accounts payable [2]. Group 2: Stock Performance - Hub Group announced a delay in releasing its fourth quarter and full year 2025 financial results, which led to a significant stock price drop of over 24% on February 6, 2026 [3][4]. - The delay was attributed to an error that understated purchased transportation costs and accounts payable, with no estimate provided for the financial impact or a timeline for restatement [3].

Core Viewpoint - A class action lawsuit has been filed against Camping World Holdings, Inc. and certain senior executives for securities fraud following significant stock drops attributed to potential violations of federal securities laws [1][4]. Group 1: Lawsuit Details - Investors have until May 11, 2026, to request to lead the case, which is pending in the U.S. District Court for the District of Illinois under the caption Siverd v. Camping World Holdings, Inc., et al. [4] - The lawsuit alleges securities fraud under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Camping World securities [4]. Group 2: Allegations Against Camping World - The lawsuit claims that Camping World misrepresented its inventory management and overstated the level of demand it experienced or reasonably expected [5][8]. - During the relevant period, Camping World expressed confidence in achieving growth in used units and maintaining vehicle gross margins within historical ranges, which is now being challenged [5]. Group 3: Stock Performance and Impact - On October 28, 2025, Camping World reported Q3 2025 financial results showing new vehicle revenue of $766.8 million, a decrease of $58.1 million or 7.0%, leading to a stock drop of $4.17 per share or 24.8% [6]. - Following the release of Q4 2025 results on February 24, 2026, which included a pause on quarterly cash dividends, the stock dropped by $1.79 per share or 16.5% [7].

Core Viewpoint - Tennant Company is under investigation for potential violations of federal securities laws related to misleading statements about its ERP system rollout, which led to significant operational disruptions and financial losses [1][3]. Group 1: Investigation Details - Bleichmar Fonti & Auld LLP is investigating Tennant for possible securities fraud concerning the implementation of a large-scale ERP system [2][3]. - The investigation focuses on whether Tennant misled investors by claiming the ERP project was "on time and on budget" and that its launch in the Asia-Pacific region was "successful" [3]. Group 2: Financial Impact - On February 24, 2026, Tennant disclosed that the ERP rollout in North America caused severe operational disruptions, resulting in an estimated loss of $30 million in sales and an increased remediation cost of over $20 million for 2026, compared to the previously planned $5 million [3]. - Following this announcement, Tennant's stock price dropped by $19.28 per share, a decline of more than 23%, from $82.30 on February 23, 2026, to $63.02 on February 24, 2026 [4]. Group 3: Legal Options for Investors - Investors in Tennant are encouraged to seek legal options and can submit their information to BFA for potential representation on a contingency fee basis [5][6].

Core Viewpoint - The Navan class action lawsuit alleges that Navan, Inc. and its executives misled investors regarding the company's financial health during its IPO, leading to significant stock price declines after the announcement of increased expenses [3][4][5]. Group 1: Class Action Lawsuit Details - The lawsuit, titled McCown v. Navan, Inc., allows purchasers of Navan's common stock from its October 31, 2025 IPO to seek lead plaintiff status by April 24, 2026 [1][2]. - Navan's IPO involved the issuance of nearly 37 million shares at an offering price of $25.00 per share [2]. - The lawsuit claims that the IPO's offering documents were materially false or misleading, particularly regarding a 39% increase in sales and marketing expenses shortly after the IPO [3]. Group 2: Financial Impact and Stock Performance - On December 15, 2025, Navan reported a 39% increase in sales and marketing expenses, rising to nearly $95 million from $68.5 million in the previous quarter [4]. - Following this announcement, Navan's stock price fell nearly 12% [4]. - By the time the lawsuit commenced, Navan's stock had traded as low as $9.20 per share, representing a nearly 63% decline from the IPO price [5]. Group 3: Legal Process and Firm Background - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Navan stock during the IPO to seek lead plaintiff status, which enables them to represent the interests of the class [6]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized as a leading firm in securities fraud litigation, having recovered over $916 million for investors in 2025 alone [7].

Core Viewpoint - A class action lawsuit has been filed against Gemini Space Station, Inc. and certain officers for alleged violations of federal securities laws related to misleading statements and omissions in the company's Offering Documents during its IPO and subsequent trading period [1][7][8]. Group 1: Lawsuit Details - The class action is on behalf of all persons and entities that purchased Gemini Class A common stock or securities between September 12, 2025, and February 17, 2026 [1]. - The lawsuit seeks to recover damages under Sections 11 and 15 of the Securities Act of 1933 and Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1]. - Investors have until May 18, 2026, to request appointment as Lead Plaintiff for the class [1]. Group 2: Company Background - Gemini was founded in 2014 to develop and operate a cryptocurrency platform, generating revenue primarily through transaction and deposit fees [2][3]. - The company aimed to expand its exchange platform by increasing monthly transacting users (MTUs), average daily trading volume, and the number of assets available [3]. Group 3: Offering Documents and IPO - Gemini's IPO occurred on September 12, 2025, with 15,178,572 shares issued at an offering price of $28.00 per share, raising approximately $398.44 million before expenses [5][6]. - The Offering Documents did not disclose any intention to prioritize a prediction market, which later became a significant aspect of the company's strategy [4][9]. Group 4: Misleading Statements and Financial Performance - The Offering Documents and company statements allegedly contained false or misleading information regarding the viability of Gemini's core business and its international expansion plans [7][8]. - On February 17, 2026, Gemini reported preliminary unaudited financial results for the fiscal year ended December 31, 2025, indicating net revenue of $165 million to $175 million and operating expenses of $520 million to $530 million, a 40% increase from the previous year [12]. Group 5: Stock Price Impact - Following the announcement of a corporate pivot to a prediction-market-centric model and workforce reduction, Gemini's stock price fell by 8.72% on February 5, 2026, and by 12.9% on February 17, 2026 [11][13].